TRANSGENE financials
TRANSGENE
969500PDJW8N0FSGGK69 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | €353.0K | €272.0K |
| Operating expenses | €42.3M | €42.0M |
| Operating profit (EBIT) | -€35.1M | -€35.7M |
| Net finance income / (cost) | -€2.5M | €1.7M |
| Profit before tax | -€37.5M | -€34.0M |
| Income tax expense | €0 | €0 |
| Profit for the year | -€37.5M | -€34.0M |
| Total comprehensive income | -€37.8M | -€33.8M |
| Per share | ||
| Basic EPS | €-0.26 | €-0.29 |
| Diluted EPS | €-0.26 | €-0.29 |
| Cash flow statement | ||
| Net cash from operating activities | -€37.0M | -€23.5M |
| Net cash from investing activities | -€106.0M | -€3.2M |
| Net cash from financing activities | €134.7M | €27.0M |
| Lease liability payments | €17.0K | €1.2M |
| Balance sheet | ||
| Total assets | €138.8M | €42.2M |
| Non-current assets | €21.1M | €21.5M |
| Current assets | €117.7M | €20.7M |
| Trade & other receivables | €3.6M | €1.2M |
| Cash & equivalents | €6.7M | €16.7M |
| Total equity | €121.7M | €15.2M |
| — attributable to owners | €121.7M | €15.2M |
| Non-current liabilities | €4.9M | €13.0M |
| Long-term borrowings | €1.7M | €10.2M |
| Current liabilities | €12.2M | €14.0M |
| Trade & other payables | €6.0M | €9.5M |
| Derived metrics | ||
| Operating margin | -25590.5% | -101880.0% |
| Net margin | -27389.8% | -97060.0% |
| Return on equity | -30.8% | -223.4% |
| Cash conversion ratio | 0.99× | 0.69× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€678.0K | -€446.0K |
| Adjustments For Depreciation and Amortisation Expense | €1.3M | €1.3M |
| Adjustments For Finance Income Cost | -€2.5M | €1.7M |
| Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities | €930.0K | -€23.0K |
| Adjustments For Increase Decrease In Other Operating Payables | €324.0K | -€95.0K |
| Adjustments For Increase Decrease In Trade Account Payable | -€3.5M | €4.9M |
| Adjustments For Provisions | €402.0K | -€492.0K |
| Adjustments For Sharebased Payments | €922.0K | €568.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€32.5M | -€34.3M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€37.8M | -€33.8M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €400.0K | €181.0K |
| Current Provisions | €979.0K | €726.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€1.7M | €799.0K |
| Equity and Liabilities | €138.8M | €42.2M |
| General and Administrative Expense | €7.3M | €7.8M |
| Increase Decrease In Cash and Cash Equivalents | -€10.0M | €1.0M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €922.0K | €568.0K |
| Increase Decrease Through Treasury Share Transactions | €67.0K | -€44.0K |
| Intangible Assets Other Than Goodwill | €49.0K | €62.0K |
| Issued Capital | €82.3M | €66.1M |
| Liabilities | €17.1M | €27.0M |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Financial Assets | €830.0K | €931.0K |
| Noncurrent Provisions For Employee Benefits | €2.7M | €2.8M |
| Number of Shares Outstanding | 274.2M | 132.3M |
| Other Adjustments For Noncash Items | -€41.0K | €0 |
| Other Comprehensive Income | -€233.0K | €196.0K |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €0 | €0 |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€3.0K | €3.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€230.0K | €193.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€3.0K | €3.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€230.0K | €193.0K |
| Other Current Nonfinancial Assets | €2.2M | €2.8M |
| Other Expense By Function | €1.1M | -€28.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | -€109.0K | -€131.0K |
| Other Longterm Provisions | €547.0K | €0 |
| Other Noncurrent Nonfinancial Liabilities | €0 | €0 |
| Payments For Share Issue Costs | €962.0K | €158.0K |
| Proceeds From Government Grants Classified As Financing Activities | €352.0K | €0 |
| Proceeds From Issuing Shares | €105.0M | €0 |
| Proceeds From Sale Or Issue of Treasury Shares | €112.0K | €111.0K |
| Property Plant and Equipment Including Rightofuse Assets | €13.5M | €14.3M |
| Reduction of Issued Capital | €0 | €0 |
| Research and Development Expense | €33.9M | €34.3M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€39.0M | -€105.8M |
| Retained Earnings Profit Loss For Reporting Period | -€37.5M | -€34.0M |
| Revenue and Operating Income | €7.2M | €6.4M |
| Revenue From Contracts With Customers | €137.0K | €35.0K |
| Revenue From Government Grants | €6.7M | €6.0M |
Every line item above is a fact tagged in TRANSGENE's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.